EGFR and non-small cell lung carcinoma: This study suggests that post-progression retreatment with EGFR-TKIs is both effective and safe in patients with locally advanced non-small cell lung cancer harboring EGFR mutations who experienced disease progression after initial gefitinib induction and chemoradiotherapy.